CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion.
Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们证明跨膜结构域在 CAR-T 细胞功能中起关键作用。
抗CD19CAR-T(CAR-T)细胞疗法已被证明可有效治疗复发/难治性B细胞急性白血病,但细胞因子释放综合征(CRS)、T细胞功能障碍和耗竭等挑战依然存在。通过改变CAR内化和再循环来增强CAR-T 细胞疗效是一种有前景的策略。跨膜结构域是在不引入额外结构域的情况下调节CAR内化及再循环最易优化的基序,但其影响尚未得到充分研究。本研究聚焦单独优化跨膜结构域设计以增强CAR-T 细胞功能。
通过质粒构建和慢病毒制备获得两种不同跨膜结构域的CAR-T 细胞[19CAR-T(1a)和19CAR-T(8)]。与肿瘤细胞共培养后评估CAR动态变化、活化水平、耗竭标志物、线粒体功能和分化状态;采用免疫荧光显微镜分析内化CAR分子定位,并通过RNA测序检测活化CAR-T 细胞转录组;最后在小鼠体内验证19CAR-T(1a)的抗肿瘤疗效。
与19CAR-T(8)相比,19CAR-T(1a)表面CAR表达较低、内化更快、再循环率更高。内化的19CAR(1a)与早期内体及再循环内体共定位更多,与溶酶体共定位更少。这些特点使19CAR-T(1a)活化水平较低、细胞因子释放较少、耗竭标志物表达减少。带有CD1a跨膜结构域的CAR-T 细胞在体内也表现出更强的抗肿瘤能力及较低耗竭程度。
跨膜结构域在CAR-T 细胞功能中发挥关键作用。优化跨膜结构域可减轻CRS并降低CAR-T 细胞耗竭,为改进CAR设计和增强CAR-T 功能提供方向。
Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective for treating relapsed or refractory acute B cell leukemia. However, challenges such as cytokine release syndrome, T cell dysfunction, and exhaustion persist. Enhancing CAR-T cell efficacy through changing CAR internalization and recycling is a promising approach. The transmembrane domain is the easiest motif to optimize for modulating CAR internalization and recycling without introducing additional domains, and its impact on CAR internalization and recycling has not yet been thoroughly explored. In this study, we aim to enhance CAR-T cell function by focusing on the solely transmembrane domain design.
Utilizing plasmid construction and lentivirus generation, we get two different transmembrane CAR-T cells [19CAR-T(1a) and 19CAR-T(8 )]. Through co-culture with tumor cells, we evaluate CAR dynamic change, activation levels, exhaustion markers, mitochondrial function, and differentiation in both CAR-T cells. Furthermore, immunofluorescence microscopy analysis is performed to reveal the localization of internalized CAR molecules. RNA sequencing is used to detect the transcriptome of activated CAR-T cells. Finally, a mouse study is utilized to verify the anti-tumor efficacy of 19CAR-T(1a) cells in vivo .
Our findings demonstrate that 19CAR-T(1a) has lower surface CAR expression, faster internalization, and a higher recycling rate compared to 19CAR-T(8 ). Internalized 19CAR(1a) co-localizes more with early and recycling endosomes, and less with lysosomes than 19CAR(8 ). These features result in lower activation levels, less cytokine release, and reduced exhaustion markers in 19CAR-T(1a). Furthermore, CAR-T cells with CD1a transmembrane domain also exhibit a superior anti-tumor ability and reduced exhaustion in vivo .
Overall, we demonstrate that the transmembrane domain plays a critical role in CAR-T cell function. An optimized transmembrane domain can alleviate cytokine release syndrome and reduce CAR-T cell exhaustion, providing a direction for CAR design to enhance CAR-T cell function.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。